<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156247">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723592</url>
  </required_header>
  <id_info>
    <org_study_id>MUW EK 1417/2012</org_study_id>
    <nct_id>NCT01723592</nct_id>
  </id_info>
  <brief_title>The Ability of Orally Administered Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.</brief_title>
  <official_title>The Ability of an Orally Administered Preparation of Four Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy. A Prospective Randomized Placebo-controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Natural Resources and Life Sciences, Vienna, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the improvement of the vaginal flora by at least two grades of the
      Nugent scale after application of oral probiotics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>change in Nugent score between baseline and end of treatment (improvement or no improvement)</measure>
    <time_frame>day 0, 7 and day 14 of oral probiotic application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using Nugent scoring system, from each participant first swab from the vagina will be taken before start of oral probiotic use.(baseline information) Second swab will be taken on the day following the last administration.(information about change in Nugent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isolation of specific Lactobacilli from vaginal microbiologic cultures after oral administration of probiotic</measure>
    <time_frame>day 0, 7 and day 14 after oral probiotic application</time_frame>
    <safety_issue>No</safety_issue>
    <description>From each participant, a vaginal swab for microbiologic cultures will be taken on the first day and that following the last administration for Isolation of oral applied probiotic strains as well as non-lactobacilli-flora.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 participants in this group receive a oral lactose placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacilli</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:
L.rhamnosus/ LbV96 (DSM 22560)
L.jensenii /LbV 116 (DSM 22567)
L.crispatus/ Lbv88 (DSM 22566)
L.gasseri /LbV 150N (DSM 22583)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains</description>
    <arm_group_label>Lactobacilli</arm_group_label>
    <other_name>L.rhamnosus/ LbV96 (DSM 22560)</other_name>
    <other_name>L.jensenii /LbV 116 (DSM 22567)</other_name>
    <other_name>L.crispatus/ Lbv88 (DSM 22566)</other_name>
    <other_name>L.gasseri /LbV 150N (DSM 22583)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral lactose placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Only women with breast cancer and neoadjuvant / adjuvant chemotherapy, at least 4 weeks
        postoperative, without vaginal bleeding without abnormal vaginal discharge, Only women
        with Nugent scores between 4 and 6

        Exclusion Criteria:

        Patients with diarrhoea, constipation, vaginal or urinary tract infection requiring
        antibacterial treatment and women receiving antibiotic therapy in the previous 4 weeks.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Kiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna, Dept. of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ljubomir Petricevic, MD</last_name>
    <phone>+431404002938</phone>
    <email>ljubomir.petricevic@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julian Marschalek, MD</last_name>
    <phone>+431404002938</phone>
    <email>julian.marschalek@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna - Department of Obstetrics and Gynecology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Marschalek, MD</last_name>
      <phone>+431404002938</phone>
      <email>julian.marschalek@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ljubomir Petricevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Assistant Prof. Ljubomir Petricevic MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>vaginal flora</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
